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therapeutic strategies addressed to these pts. At first it has 
become evident that any age-cut-off adopted to identify 
“elderly pts” ( > 65 yo, > 75 yo or even > 85 yo) has intrinsic 
limitations because geriatric pts are an extremely 
heterogeneous group with respect to their general health 
status. Second, a comprehensive geriatric assessment is 
needed to stratify and weigh the spectrum of 
dysfunctions present at old ages in order to select pts 
suitable for treatment (with standard protocol or with 
adapted ones). Several instruments and screening tools are 
proposed in the literature aiming at evaluate the 
vulnerability of elderly cancer pts: from complex and time 
consuming procedures to more easy to apply ones and to self-
administered questionnaires based on self-assessment of a 
short list of items. Finally elderly pts should be evaluated 
during and after their cancer treatments in order to detect 
signs and symptoms related to potential complications due to 
the treatment itself in order to eventually modulate it 
accordingly. 
Brachytherapy (BT) is an attractive treatment option for 
elderly cancer patients and this is especially true for prostate 
and gynaecological malignancies. The International Society of 
Geriatric Oncology (SIOG) Radiotherapy Task Force has 
reviewed the current best practice and priorities for research 
in radiation oncology for elderly patients with cancer. It has 
been stated that life expectancy and comorbidities should 
influence the selection criteria for prostate BT and that an 
international consensus is needed to define the subset of 
geriatric pts for prospective evaluation of BT acknowledging 
that a specific literature on BT for this group of cancer pts is 
virtually non-existent. Interestingly enough the same paper 
addresses the issue of BT (vaginal Brachytherapy, VBT) for 
postoperative irradiation of pts diagnosed with Endometrial 
cancer (ECa) in the Intermediate to High Risk Group. The 
PORTEC-2 Trial has found no significant differences between 
external beam RT and VBT in pts > 60 years old in terms of 
local or distant recurrence rates, but with a reduced toxicity 
and improved quality of life making VBT the adjuvant 
treatment option in this setting. Furthermore, the last up-
date of the Guidelines of the European Association of Urology 
(EAU) devotes a specific chapter to the Management of 
Prostate Cancer in Older Men, recognizing that this is 
a specific subgroup of PCa pts emphasizing that, according to 
published results from the US Surveillance Epidemiology and 
End Results (SEER) database, 71 % of PCa-related deaths 
occur in men aged ≥ 75 years. Surprisingly enough, after a list 
of rather generic recommendations about the need of a 
comprehensive baseline evaluation of life expectancy, 
comorbidities and health status, BT is not even mentioned in 
the paragraph devoted to the treatment of localized 
disease…On the contrary, the recently published Updated 
recommendations of the working party on the management 
of PCa of the SIOG, clearly states that BT “can be a suitable 
option for older men with PCa”, but any further details is 
given concerning the profile of the “suitable” pts. 
In conclusion, the general picture of the management of 
older pts with PCa or gynaecological malignancies is rapidly 
changing: particular attention is nowadays reserved to this 
subset of pts. Specific and details guidelines are still lacking 
but the oncological community is aware of the importance of 
a tailored approach that has to take into account a correct 
evaluation of the baseline profile of the pt before any 
treatment can be proposed.    
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Experimental microdosimetry is performed with TEPC (Tissue 
Equivalent Proportional Counter) that are able to measure 
the stochastic of radiation interaction with micrometric 
sensitive volumes. To measure ionizations produced in 
microscopic site with a macroscopic volume, TEPC are filled 
with low-pressure gas. At Legnaro National Laboratories of 
INFN new TEPC have been developed that are able to 
measure high intensity therapeutic beams. They are called 
mini-TEPC because of their small dimensions of the sensitive 
volume. Moreover, miniaturization involves also the external 
dimensions since the counter is inserted in a titanium sleeve 
of 2.7mm external diameter. Mini-TEPCs have been tested 
under different fields. With proton beams, they showed that 
is possible to assess the RBE of proton beam by using a proper 
weighting function.  
It is possible to perform microdosimetry at nanometric level, 
at least down to 25nm, with an avalanche confinement TEPC. 
An Italian research project called MITRA is developing this 
kind of detector for ion beams.  
Finally, in the world there are only three operative 
nanodosimeters. They measure the track structure of the 
beam: two of them are able to measure the track structure 
due to the beam core and the penumbra. The BioQuaRT 
project compared the responses of the three nanodosimeters. 
The three nanodosimeters are very different as well as their 
outputs in terms of ICSD (Ionization Cluster Size 
Distributions). However, the sum distribution Fk versus M1 of 
the three devices forms an almost perfect universal curve, 
and shows a saturation effect like radio-biological cross 
sections as a function of LET. 
Results will be presented.  
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Monte Carlo simulations are commonly used in radiobiology or 
medical applications for evaluating the energy deposition of 
ionizing radiation in biological targets. Nevertheless, trying 
to predict the earlier radio-induced biological effects in a 
cell population starting from an accurate description of the 
energy deposition at their origin needs the development of 
dedicated simulation tools. The first requirement of these 
simulation tools is their capability to calculate the track 
structure of the ionizing radiation with nanometric precision. 
Indeed, the nanometer scale corresponds to molecular 
dimensions and in particular to the scale of the DNA molecule 
that is the main target for which radiation damages can be 
linked to mutagenic or even lethal effects. Several dedicated 
simulation tools for this purpose have been developed in the 
last decades, following a mechanistic approach for the 
simulation of early radiation-induced biological effects. In 
